Abstract: A method for the purification of cyclic indole compounds that provides advantages over previously-known methods. Using the method of the present invention allows for the facile preparation of a good quality solid form of these compounds.

Abstract: The present invention provides a new chemical process, a new cassette configuration, and new software for the automated production of multiple batches of an [18F]labelled compound on a single cassette. The invention allows one synthesizer in one hot cell to produce sequentially a plurality of batches of [18F]-labelled PET tracer in the same day. In particular, the present invention provides a novel arrangement useful for the trapping of [18F]fluoride and recovery of [18O]water.

Abstract: The present invention provides a new chemical process, a new cassette configuration, and new software for the automated production of multiple batches of an [18F]-labelled compound on a single cassette. The invention allows one synthesizer in one hot cell to produce sequentially a plurality of batches of [18F]-labelled PET tracer in the same day. In particular, the present invention provides a novel arrangement useful for purifying two consecutive batches of a reaction mixture comprising an 18F-labelled compound.

Abstract: The present invention provides a method of purifying 68Ge/68Ga generator produced 68Ga from Fe (III). The invention further relates to an automated system within an existing Gallea Synthia prototype that provides purification 68Ga from various cations and preconcentrations of 68Ga. In general, the present invention further depicts the use of an automated system for the production of 68Ga-radiolabelled PET tracers with high specific radioactivity and a kit for purifying 68Ge/68Ga generator produced 68Ga from Fe (III).

Abstract: An object of the present invention is to provide a probe for imaging a ?-sheet structure protein which can be used for the diagnosis of conformational diseases, particularly disease (tauopathy) having a cardinal symptom such as intracerebral accumulation of tau protein, for example, Alzheimer's disease. Another object of the present invention is to provide a compound which is highly specific to tau and can image tau with satisfactory sensitivity, and also has high brain transition, low or non-recognized bone-seeking properties and low or non-recognized toxicity. According to the present invention, the above problems are solved by providing a compound of a formula I (wherein A, R1, R2, R3, R4, R5, R6, Ra and Rb are as defined in the present description) or a pharmaceutically acceptable salt or solvate thereof.

Abstract: The present invention relates to stabilised 99mTc radiopharmaceutical compositions of the ligand tetrofosmin, which include an ascorbic acid or ascorbate radioprotectant, in the absence of an antimicrobial preservative. The invention also provides lyophilised kits suitable for the bulk preparation of multiple unit patient doses of 99mTc-tetrofosmin metal complexes. Also disclosed are unit doses of 99mTc-tetrofosmin, together with processes for preparing such unit doses from the lyophilised bulk vial.

Abstract: The present invention provides an automated method for the preparation of 123I-labelled radiopharmaceutical compositions, together with disposable cassettes for use in the method. The use of an automated synthesizer apparatus in the preparation of 123I-labelled radiopharmaceuticals is also described. Also described is the use of cassettes of the present invention in the preparation of 123I-labelled radiopharmaceuticals.

Abstract: A method of radiostabilizing an oxime ligation or imine formation reaction using aniline is described.

Abstract: The present invention provides a 99mTc-tetrofosmin radiopharmaceutical composition comprising tetrofosmin and a radioprotectant at a particular range of molar ratios. A kit and a multi-dose kit for the preparation of the radiopharmaceutical composition of the invention are also provided, as well as a process for the preparation of multiple unit patient doses of the radiopharmaceutical composition and a unit dose of the radiopharmaceutical composition.

Abstract: A sterile dispense system provides for transfer of a fluid from a disposable fluid-path to a vial without needles piercing the vial stopper, for disconnecting the vial from the disposable fluid-path while keeping integrity of the solution filled into the vial and to enable withdrawing of the solution from the vial. The pressure valve and luer valve are provided in serial connection to a fluid vial to enable clean filling and dispensing from the vial.

Abstract: The present invention relates to imaging agent compositions comprising radiolabelled c-Met binding peptides suitable for positron emission tomography (PET) imaging in vivo. The c-Met binding peptides are labelled with the radioisotope 18F. Also disclosed are pharmaceutical compositions, methods of preparation of the agents and compositions, plus methods of in vivo imaging using the compositions, especially for use in the management of cancer.

Abstract: The present invention relates to the field of radiopharmaceuticals for in vivo imaging, in particular to a method of labelling a biological targeting molecule with a radioisotope. The method of the invention is particularly suitable for use with an automated synthesizer apparatus. Also provided are precursors in sterile form, as well as cassettes comprising such precursors useful in the method.

Abstract: The present invention provides a method of purifying 68Ge/68Ga generator produced 68Ga from Fe (III). The invention further relates to an automated system within an existing Gallea Synthia prototype that provides purification 68Ga from various cations and preconcentrations of 68Ga. In general, the present invention further depicts the use of an automated system for the production of 68Ga-radiolabelled PET tracers with high specific radioactivity and a kit for purifying 68Ge/68Ga generator produced 68Ga from Fe (III).

Abstract: The present invention concerns in vivo imaging and in particular in vivo imaging of the peripheral benzodiazepine receptor (PBR). A tetracyclic indole in vivo imaging agent is provided that binds with high affinity to PBR, has good uptake into the brain following administration, and which preferentially binds to tissues expressing higher levels of PBR. The present invention also provides a precursor compound useful in the synthesis of the in vivo imaging agent of the invention, as well as a method for synthesis of said in vivo imaging agent comprising use of said precursor compound, and a kit for carrying out said method. A cassette for the automated synthesis of the in vivo imaging agent is also provided. In addition, the invention provides a radiopharmaceutical composition comprising the in vivo imaging agent of the invention, as well as methods for the use of said in vivo imaging agent.

Abstract: The present invention relates to a method for the production of tricyclic indole compounds comprising a cyclization step wherein this step is improved over known methods.

Abstract: The present invention relates to improved 18F-labelled aldehyde compositions, wherein impurities which affect imaging in vivo are identified and suppressed. Also provided are methods of preparation of radiofluorinated biological targeting molecules using said improved compositions, together with radiopharmaceutical compositions. The invention also includes methods of imaging and/or diagnosis using the radiopharmaceutical compositions described.

Abstract: The present invention relates to the field of radiopharmaceuticals for in vivo imaging, in particular to a method of purifying a radiotracer which comprises 18F-labelled aminoxy-functionalised biological targeting moiety. The invention provides radioprotectant-containing radiopharmaceutical compositions of the tracers, as well as associated automated methods and cassettes.

Abstract: The invention relates to a process for preparation of a compound of formula (I): R1 is selected from C1-6alkyl, C2-6alkenyl, and C2-6alkynyl; which comprises: (i) reaction with fluoride, suitably [18F]fluoride, of a corresponding compound of formula (II): wherein R2 is selected from hydrogen, C1-10alkyl, C1-10haloalkyl, C6-14aryl, C6-14arylalkyl, —(CH2CH2O)q—CH3 wherein q is an integer of from 1 to 10; R1 is as defined for the compound of formula (I); and R3 is a leaving group. Certain novel precursors of formula (II) and radiopharmaceutical kits containing such precursors are also claimed.

Abstract: A pierce and fill connector cap for a vial sealed by an elastomeric septum includes a vial collar and a needle holder. The vial collar body defines a collar aperture to be positioned in overlying registry with the septum of the vial, and the needle holder includes a needle holder body providing a means for holding a pair of elongate needles in registry with the collar aperture. The needle holder body holds at least one needle therein in a bent or deflected orientation and is moveable with respect to the vial collar between a first position spaced from the vial collar and a second position proximate the vial collar, such that the needled held by the needle holder will puncture through the vial septum.

Abstract: An object of the present invention is to provide a probe for imaging a ?-sheet structure protein which can be used for the diagnosis of conformational diseases, particularly disease (tauopathy) having a cardinal symptom such as intracerebral accumulation of tau protein, for example, Alzheimer's disease. Another object of the present invention is to provide a compound which is highly specific to tau and can image tau with satisfactory sensitivity, and also has high brain transition, low or non-recognized bone-seeking properties and low or non-recognized toxicity. According to the present invention, the above problems are solved by providing a compound of a formula I (wherein A, R1, R2, R3, R4, R5, R6, Ra and Rb are as defined in the present description) or a pharmaceutically acceptable salt or solvate thereof.